Trial Profile
A retrospective, observational study to evaluate the clinical and functional improvement of patients with persistent severe asthma treated with omalizumab for 5 years.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- 17 Mar 2016 New trial record
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology